Switch to:
Also traded in: Brazil, Chile, Germany, Mexico, Switzerland

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.40
GILD's Cash to Debt is ranked lower than
89% of the 952 Companies
in the Global Biotechnology industry.

( Industry Median: 49.03 vs. GILD: 0.40 )
Ranked among companies with meaningful Cash to Debt only.
GILD' s Cash to Debt Range Over the Past 10 Years
Min: 0.15  Med: 1.33 Max: 4122.75
Current: 0.4
0.15
4122.75
Equity to Asset 0.31
GILD's Equity to Asset is ranked lower than
83% of the 698 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. GILD: 0.31 )
Ranked among companies with meaningful Equity to Asset only.
GILD' s Equity to Asset Range Over the Past 10 Years
Min: 0.21  Med: 0.58 Max: 0.95
Current: 0.31
0.21
0.95
Interest Coverage 23.94
GILD's Interest Coverage is ranked lower than
80% of the 456 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GILD: 23.94 )
Ranked among companies with meaningful Interest Coverage only.
GILD' s Interest Coverage Range Over the Past 10 Years
Min: 11.11  Med: 36.36 Max: 165.23
Current: 23.94
11.11
165.23
F-Score: 5
Z-Score: 4.49
M-Score: -2.54
WACC vs ROIC
8.34%
64.98%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 63.00
GILD's Operating margin (%) is ranked higher than
97% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -85.53 vs. GILD: 63.00 )
Ranked among companies with meaningful Operating margin (%) only.
GILD' s Operating margin (%) Range Over the Past 10 Years
Min: -25.07  Med: 50.02 Max: 68
Current: 63
-25.07
68
Net-margin (%) 50.50
GILD's Net-margin (%) is ranked higher than
97% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -80.71 vs. GILD: 50.50 )
Ranked among companies with meaningful Net-margin (%) only.
GILD' s Net-margin (%) Range Over the Past 10 Years
Min: -39.32  Med: 36.8 Max: 55.48
Current: 50.5
-39.32
55.48
ROE (%) 100.69
GILD's ROE (%) is ranked higher than
99% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -32.34 vs. GILD: 100.69 )
Ranked among companies with meaningful ROE (%) only.
GILD' s ROE (%) Range Over the Past 10 Years
Min: -49.14  Med: 48.5 Max: 106.64
Current: 100.69
-49.14
106.64
ROA (%) 34.14
GILD's ROA (%) is ranked higher than
98% of the 955 Companies
in the Global Biotechnology industry.

( Industry Median: -27.67 vs. GILD: 34.14 )
Ranked among companies with meaningful ROA (%) only.
GILD' s ROA (%) Range Over the Past 10 Years
Min: -30.31  Med: 29.12 Max: 42.28
Current: 34.14
-30.31
42.28
ROC (Joel Greenblatt) (%) 627.83
GILD's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: -358.44 vs. GILD: 627.83 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GILD' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -71.55  Med: 176.02 Max: 627.83
Current: 627.83
-71.55
627.83
Revenue Growth (3Y)(%) 51.80
GILD's Revenue Growth (3Y)(%) is ranked higher than
90% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. GILD: 51.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
GILD' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 7.8  Med: 37.5 Max: 70.4
Current: 51.8
7.8
70.4
EBITDA Growth (3Y)(%) 79.10
GILD's EBITDA Growth (3Y)(%) is ranked higher than
96% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. GILD: 79.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
GILD' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -13.7  Med: 38.05 Max: 116.7
Current: 79.1
-13.7
116.7
EPS Growth (3Y)(%) 93.70
GILD's EPS Growth (3Y)(%) is ranked higher than
97% of the 501 Companies
in the Global Biotechnology industry.

( Industry Median: -3.60 vs. GILD: 93.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
GILD' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -19.7  Med: 30.35 Max: 143.5
Current: 93.7
-19.7
143.5
» GILD's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-27)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

GILD Guru Trades in Q3 2015

Keeley Asset Management Corp 29,029 sh (New)
John Burbank 29,586 sh (+1189.15%)
Ray Dalio 222,121 sh (+171.80%)
RS Investment Management 156,503 sh (+24.37%)
John Rogers 1,313,500 sh (+18.71%)
David Dreman 11,228 sh (+17.88%)
NWQ Managers 169,500 sh (+16.74%)
Murray Stahl 9,950 sh (+11.17%)
John Buckingham 61,912 sh (+7.97%)
Pioneer Investments 3,283,529 sh (+0.28%)
David Carlson 550,000 sh (unchged)
John Hussman 75,000 sh (unchged)
First Eagle Investment 400 sh (unchged)
Westport Asset Management 95,000 sh (unchged)
Lee Ainslie 2,340 sh (unchged)
Dodge & Cox 4,250 sh (unchged)
Jeremy Grantham 3,600 sh (unchged)
Louis Moore Bacon Sold Out
Ronald Muhlenkamp 217,990 sh (-0.29%)
Mario Gabelli 43,750 sh (-0.40%)
Julian Robertson 352,311 sh (-11.79%)
Joel Greenblatt 936,982 sh (-12.28%)
Ken Fisher 562,391 sh (-28.96%)
Paul Tudor Jones 7,300 sh (-29.67%)
Jim Simons 280,300 sh (-78.60%)
» More
Q4 2015

GILD Guru Trades in Q4 2015

Jeff Auxier 2,282 sh (New)
Diamond Hill Capital 2,070 sh (New)
Louis Moore Bacon 20,493 sh (New)
T Rowe Price Equity Income Fund 1,250,000 sh (New)
Jerome Dodson 200,000 sh (New)
Jim Simons 2,319,448 sh (+727.49%)
Paul Tudor Jones 16,614 sh (+127.59%)
Julian Robertson 394,411 sh (+11.95%)
Pioneer Investments 3,392,997 sh (+3.33%)
John Buckingham 63,796 sh (+3.04%)
Murray Stahl 10,000 sh (+0.50%)
Ken Fisher 563,917 sh (+0.27%)
David Carlson 550,000 sh (unchged)
Westport Asset Management 95,000 sh (unchged)
John Rogers 1,313,500 sh (unchged)
Jeremy Grantham 3,600 sh (unchged)
Lee Ainslie 2,340 sh (unchged)
First Eagle Investment 400 sh (unchged)
Samuel Isaly 327,100 sh (unchged)
John Hussman Sold Out
Keeley Asset Management Corp Sold Out
John Burbank Sold Out
David Dreman Sold Out
Ronald Muhlenkamp 217,975 sh (-0.01%)
RS Investment Management 155,231 sh (-0.81%)
NWQ Managers 166,900 sh (-1.53%)
Ray Dalio 218,121 sh (-1.80%)
Mario Gabelli 42,700 sh (-2.40%)
Joel Greenblatt 874,246 sh (-6.70%)
Dodge & Cox 3,750 sh (-11.76%)
» More
Q1 2016

GILD Guru Trades in Q1 2016

David Dreman 23,210 sh (New)
Leon Cooperman 516,989 sh (New)
George Soros 3,600 sh (New)
Steven Cohen 700 sh (New)
Jeremy Grantham 97,600 sh (+2611.11%)
First Eagle Investment 9,200 sh (+2200.00%)
Paul Tudor Jones 41,349 sh (+148.88%)
Lee Ainslie 5,630 sh (+140.60%)
Dodge & Cox 7,620 sh (+103.20%)
Jerome Dodson 310,000 sh (+55.00%)
Jeff Auxier 2,982 sh (+30.67%)
Ray Dalio 249,821 sh (+14.53%)
Joel Greenblatt 967,642 sh (+10.68%)
Pioneer Investments 3,700,967 sh (+9.08%)
T Rowe Price Equity Income Fund 1,353,600 sh (+8.29%)
David Carlson 570,000 sh (+3.64%)
John Rogers 1,360,492 sh (+3.58%)
Ronald Muhlenkamp 217,990 sh (+0.01%)
Murray Stahl 10,000 sh (unchged)
Ronald Muhlenkamp 3,200 sh (unchged)
Westport Asset Management 95,000 sh (unchged)
Samuel Isaly 327,100 sh (unchged)
Diamond Hill Capital Sold Out
Louis Moore Bacon Sold Out
John Buckingham 63,487 sh (-0.48%)
RS Investment Management 151,102 sh (-2.66%)
Mario Gabelli 40,690 sh (-4.71%)
Ken Fisher 487,030 sh (-13.63%)
NWQ Managers 116,000 sh (-30.50%)
Jim Simons 723,948 sh (-68.79%)
Julian Robertson 38,511 sh (-90.24%)
» More
Q2 2016

GILD Guru Trades in Q2 2016

Zeke Ashton 21,500 sh (New)
John Burbank 730,472 sh (New)
Steven Cohen 659,100 sh (+94057.14%)
Jeremy Grantham 423,100 sh (+333.50%)
First Eagle Investment 15,500 sh (+68.48%)
Ray Dalio 374,672 sh (+49.98%)
Jim Simons 1,079,348 sh (+49.09%)
David Carlson 730,000 sh (+28.07%)
Lee Ainslie 7,020 sh (+24.69%)
John Rogers 1,443,305 sh (+6.09%)
Joel Greenblatt 1,016,142 sh (+5.01%)
T Rowe Price Equity Income Fund 1,375,000 sh (+1.58%)
Murray Stahl 10,050 sh (+0.50%)
John Buckingham 63,649 sh (+0.26%)
Julian Robertson 38,511 sh (unchged)
Jeff Auxier 2,982 sh (unchged)
Westport Asset Management 95,000 sh (unchged)
Ronald Muhlenkamp 3,200 sh (unchged)
Samuel Isaly 327,100 sh (unchged)
George Soros Sold Out
Leon Cooperman Sold Out
Ronald Muhlenkamp 217,000 sh (-0.45%)
David Dreman 22,546 sh (-2.86%)
Pioneer Investments 3,465,144 sh (-6.37%)
NWQ Managers 108,300 sh (-6.64%)
Ken Fisher 446,493 sh (-8.32%)
Mario Gabelli 35,819 sh (-11.97%)
Jerome Dodson 265,000 sh (-14.52%)
Dodge & Cox 3,750 sh (-50.79%)
Paul Tudor Jones 13,751 sh (-66.74%)
RS Investment Management 29,512 sh (-80.47%)
» More
» Details

Insider Trades

Latest Guru Trades with GILD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NYSE:NVO, NAS:CELG, NAS:AMGN, NAS:BIIB, NAS:SHPG, NAS:REGN, OTCPK:CSLLY, NAS:ALXN, OTCPK:NVZMY, NAS:VRTX, OTCPK:ALIOY, NAS:INCY, NAS:BMRN, OTCPK:UCBJF, NAS:MDVN, OTCPK:GMXAY, NAS:SGEN, NAS:JAZZ, NAS:ALKS, NAS:ALNY » details
Traded in other countries:GILD34.Brazil, GILD.Chile, GIS.Germany, GILD.Mexico, GILD.Switzerland,
Gilead Sciences Inc is a research-based biopharmaceutical company that discovers, develops and commercializes new medicines for different medical sectors.

Gilead Sciences Inc was incorporated in Delaware on June 22, 1987. The Company is a research-based biopharmaceutical company that discovers, develops and commercializes new medicines for different medical sectors. With each new discovery and experimental drug candidate, it seeks to improve the care of patients suffering from life-threatening diseases around the world. The Company's primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, cardiovascular, hematology/oncology and inflammation/respiratory. Its operations include offices in Europe, North America, Asia, South America, Africa, Australia, India and the Middle East. It markets products in the HIV, liver diseases, respiratory and cardiovascular/metabolic therapeutic areas. The Company's products comprise of, Truvada, which is an oral formulation dosed once a day as part of combination therapy to treat human immunodeficiency virus infection in adults. Atripla is an oral formulation dosed once a day for the treatment of HIV infection in adults. Viread is an oral formulation of a nucleotide analogue reverse transcriptase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in adults. Emtriva is an oral formulation of a nucleoside analogue reverse transcriptase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in adults. Hepsera is an oral formulation of a nucleotide analogue polymerase inhibitor, dosed once a day to treat chronic hepatitis B. AmBisome is a proprietary liposomal formulation of amphotericin B, an antifungal agent to treat serious invasive fungal infections caused by various fungal species. Letairis is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension in patients with WHO Class II or III symptoms to improve exercise capacity and delay clinical worsening. Ranexa is indicated for the treatment of chronic angina. Vistide is an antiviral medication for the treatment of cytomegalovirus retinitis in patients with AIDS. Cayston is an inhaled antibiotic as a treatment to improve respiratory systems in cystic fibrosis patients with Pseudomonas aeruginosa. The Company sells and distributes Truvada, Viread, Emtriva, Hepsera and AmBisome in Europe, Australia and New Zealand either through its commercial teams, third party distributors or corporate partners. The Company's products compete with other available products based mainly on: efficacy; safety; tolerability; acceptance by doctors; ease of patient compliance; patent protection; ease of use; price; insurance and other reimbursement coverage; distribution; and marketing. The Company owns various trademarks and trade names used in its business, including the following: GILEAD, GILEAD SCIENCES, TRUVADA, VIREAD, HEPSERA, AMBISOME, EMTRIVA, VISTIDE, LETAIRIS, VOLIBRIS(tm), RANEXA and CAYSTON. The C

Guru Investment Theses on Gilead Sciences Inc

Jerome Dodson Comments on Gilead - Jul 26, 2016

Gilead (NASDAQ:GILD), a biotechnology firm that makes therapies for HIV and hepatitis C, sliced 21 basis points off the Fund’s return, as its stock declined 9.2% from $91.86 to $83.42. The company’s underperformance was driven by weakness in its hepatitis C business, as pricing came under pressure due to increased competition. Given Gilead’s proven track record of innovation and its strong balance sheet, we believe the company has many opportunities, not only to maintain leadership in HIV and hepatitis C, but also to expand its portfolio into new therapeutic areas.


From Jerome Dodson (Trades, Portfolio)'s Parnassus Fund second quarter 2016 commentary.

Check out Jerome Dodson latest stock trades

John Rogers Comments on Gilead Sciences Inc. - Dec 02, 2015

Biotechnology leader Gilead Sciences, Inc. (NASDAQ:GILD) dropped -15.90% on recent concerns over drug pricing. Gilead actually reported quarterly earnings that were better than expected. We continue to hold the shares, based on our belief that the market is overly focused on pricing and underestimating future sales that we think are likely to grow.





From John Rogers (Trades, Portfolio) 3rd quarter commentary on the Ariel Global Fund.

Check out John Rogers latest stock trades

Top Ranked Articles about Gilead Sciences Inc

Gilead Sciences: Cheap Growth or Value Trap? GILD has plunged over 30% since its peak in mid-2015 and now trades for less than 10 times earnings. Are the best days behind the company, or is GILD a bargain?
Gilead Sciences (NASDAQ:GILD), the dominant antiviral and hepatitis drug company, is starting to draw a lot of attention from value oriented investors due to its decline of 23% over the past year. Read more...
5 Undervalued Stocks Near Lows for Enterprising Value Investors These companies were selected and evaluated by ModernGraham
Jerome Dodson Comments on Gilead Guru stock highlight
Gilead (NASDAQ:GILD), a biotechnology firm that makes therapies for HIV and hepatitis C, sliced 21 basis points off the Fund’s return, as its stock declined 9.2% from $91.86 to $83.42. The company’s underperformance was driven by weakness in its hepatitis C business, as pricing came under pressure due to increased competition. Given Gilead’s proven track record of innovation and its strong balance sheet, we believe the company has many opportunities, not only to maintain leadership in HIV and hepatitis C, but also to expand its portfolio into new therapeutic areas.
Read more...
5 Best Stocks For Value Investors This Week These companies were identified and reviewed by ModernGraham
We evaluated 31 different companies this week to determine whether they are suitable for Defensive Investors, those unwilling to do substantial research, or Enterprising Investors, those who are willing to do such research. We also put each company through the ModernGraham valuation model based on Benjamin Graham's value investing formulas in order to determine an intrinsic value for each. Out of those 31 companies, only 5 were found to be undervalued or fairly valued and suitable for either Defensive or Enterprising Investors. Read more...
Gilead Sciences Insider Sells 112,000 Shares Transaction nets $9.4 million for CEO
John Milligan (Insider Trades), CEO and president of Gilead Sciences Inc. (GILD), sold 112,000 company shares on July 5. The price per share was $84.33 for a total transaction of $9,444,960. Read more...
Wall Street Estimates and Biopharma Value Investing There are no 'legal' shortcuts to evaluating health care opportunities
Gilead and Celgene Among Biotechnology Stocks to Buy Industry contains at least 2 stocks that gurus are adding to their portfolios
The general biotechnology industry offers gurus many opportunities to increase their portfolio returns. Several biotech stocks, including Gilead Sciences Inc. (NASDAQ:GILD) and Celgene Corp. (NASDAQ:CELG), have positive financial outlooks. Read more...
Gilead, Fossil Among Stocks Trading Below Lynch Earnings Line Using Peter Lynch's valuation method to find investment ideas
Former Magellan fund manager Peter Lynch devised a method of determining whether stocks are over or undervalued by equating $1 in earnings with $15 in stock price. The earnings line was introduced in his best-selling book “One Up on Wall Street.” Read more...
Weekly CEO Sells Highlight: Gilead Sciences, Boston Scientific, Sonic, HealthEquity Recent insider sells from company CEOs
According to GuruFocus Insider Data, these are the largest CEO sells during the past week: Gilead Sciences Inc., Boston Scientific Corp., Sonic Corp. and HealthEquity Inc. Read more...
A Look Back at 2 Successful Biotech Buyouts Pharmasset and Idenix were both acquired at huge premiums
The biotech pharmaceutical business is all about clinical trials, FDA approvals and the potential market its addresses. Most of the biotech companies experienced rising stock market prices despite the fact that it had consistently generated negative earnings over time. The negative earnings were due to the high R&D expenses it occurred during the testing and clinical trials phase. Normally, those biotech companies would be acquired by larger, established pharmaceutical firms at a huge premium to its stock price. They got acquired not because of their earnings they have generated in the past, but because of the current drug pipelines, which could create a lot of cash flow in the future. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 7.17
GILD's P/E(ttm) is ranked higher than
90% of the 232 Companies
in the Global Biotechnology industry.

( Industry Median: 28.59 vs. GILD: 7.17 )
Ranked among companies with meaningful P/E(ttm) only.
GILD' s P/E(ttm) Range Over the Past 10 Years
Min: 6.77  Med: 18.48 Max: 45.49
Current: 7.17
6.77
45.49
Forward P/E 6.99
GILD's Forward P/E is ranked higher than
87% of the 64 Companies
in the Global Biotechnology industry.

( Industry Median: 19.23 vs. GILD: 6.99 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 7.17
GILD's PE(NRI) is ranked higher than
91% of the 232 Companies
in the Global Biotechnology industry.

( Industry Median: 28.70 vs. GILD: 7.17 )
Ranked among companies with meaningful PE(NRI) only.
GILD' s PE(NRI) Range Over the Past 10 Years
Min: 6.77  Med: 18.47 Max: 45.49
Current: 7.17
6.77
45.49
Price/Owner Earnings (ttm) 6.49
GILD's Price/Owner Earnings (ttm) is ranked higher than
86% of the 135 Companies
in the Global Biotechnology industry.

( Industry Median: 31.24 vs. GILD: 6.49 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
GILD' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 6.14  Med: 17.46 Max: 74.51
Current: 6.49
6.14
74.51
P/B 6.97
GILD's P/B is ranked lower than
73% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: 3.70 vs. GILD: 6.97 )
Ranked among companies with meaningful P/B only.
GILD' s P/B Range Over the Past 10 Years
Min: 4.15  Med: 8.37 Max: 18.71
Current: 6.97
4.15
18.71
P/S 3.64
GILD's P/S is ranked higher than
77% of the 680 Companies
in the Global Biotechnology industry.

( Industry Median: 11.96 vs. GILD: 3.64 )
Ranked among companies with meaningful P/S only.
GILD' s P/S Range Over the Past 10 Years
Min: 3.44  Med: 7.27 Max: 14.38
Current: 3.64
3.44
14.38
PFCF 6.91
GILD's PFCF is ranked higher than
92% of the 119 Companies
in the Global Biotechnology industry.

( Industry Median: 28.24 vs. GILD: 6.91 )
Ranked among companies with meaningful PFCF only.
GILD' s PFCF Range Over the Past 10 Years
Min: 6.51  Med: 20.29 Max: 57.83
Current: 6.91
6.51
57.83
POCF 6.59
GILD's POCF is ranked higher than
91% of the 181 Companies
in the Global Biotechnology industry.

( Industry Median: 22.40 vs. GILD: 6.59 )
Ranked among companies with meaningful POCF only.
GILD' s POCF Range Over the Past 10 Years
Min: 6.23  Med: 18.22 Max: 51.28
Current: 6.59
6.23
51.28
EV-to-EBIT 5.87
GILD's EV-to-EBIT is ranked higher than
83% of the 239 Companies
in the Global Biotechnology industry.

( Industry Median: 23.08 vs. GILD: 5.87 )
Ranked among companies with meaningful EV-to-EBIT only.
GILD' s EV-to-EBIT Range Over the Past 10 Years
Min: -154.2  Med: 13.7 Max: 209.2
Current: 5.87
-154.2
209.2
EV-to-EBITDA 5.57
GILD's EV-to-EBITDA is ranked higher than
83% of the 258 Companies
in the Global Biotechnology industry.

( Industry Median: 19.61 vs. GILD: 5.57 )
Ranked among companies with meaningful EV-to-EBITDA only.
GILD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -189.9  Med: 12.85 Max: 168
Current: 5.57
-189.9
168
PEG 0.16
GILD's PEG is ranked higher than
98% of the 91 Companies
in the Global Biotechnology industry.

( Industry Median: 2.22 vs. GILD: 0.16 )
Ranked among companies with meaningful PEG only.
GILD' s PEG Range Over the Past 10 Years
Min: 0.12  Med: 0.59 Max: 3.75
Current: 0.16
0.12
3.75
Shiller P/E 23.52
GILD's Shiller P/E is ranked higher than
75% of the 56 Companies
in the Global Biotechnology industry.

( Industry Median: 46.41 vs. GILD: 23.52 )
Ranked among companies with meaningful Shiller P/E only.
GILD' s Shiller P/E Range Over the Past 10 Years
Min: 22.22  Med: 56.93 Max: 2078
Current: 23.52
22.22
2078
Current Ratio 1.76
GILD's Current Ratio is ranked lower than
79% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: 4.42 vs. GILD: 1.76 )
Ranked among companies with meaningful Current Ratio only.
GILD' s Current Ratio Range Over the Past 10 Years
Min: 1.09  Med: 5.97 Max: 19.04
Current: 1.76
1.09
19.04
Quick Ratio 1.58
GILD's Quick Ratio is ranked lower than
77% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: 4.19 vs. GILD: 1.58 )
Ranked among companies with meaningful Quick Ratio only.
GILD' s Quick Ratio Range Over the Past 10 Years
Min: 0.83  Med: 5.48 Max: 19.04
Current: 1.58
0.83
19.04
Days Inventory 169.70
GILD's Days Inventory is ranked lower than
63% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 132.15 vs. GILD: 169.70 )
Ranked among companies with meaningful Days Inventory only.
GILD' s Days Inventory Range Over the Past 10 Years
Min: 148.53  Med: 224.63 Max: 328.95
Current: 169.7
148.53
328.95
Days Sales Outstanding 64.86
GILD's Days Sales Outstanding is ranked lower than
52% of the 586 Companies
in the Global Biotechnology industry.

( Industry Median: 62.03 vs. GILD: 64.86 )
Ranked among companies with meaningful Days Sales Outstanding only.
GILD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 64.86  Med: 70.56 Max: 84.93
Current: 64.86
64.86
84.93
Days Payable 97.90
GILD's Days Payable is ranked higher than
67% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 54.96 vs. GILD: 97.90 )
Ranked among companies with meaningful Days Payable only.
GILD' s Days Payable Range Over the Past 10 Years
Min: 92.02  Med: 172.89 Max: 309.16
Current: 97.9
92.02
309.16

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.21
GILD's Dividend Yield is ranked higher than
73% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 1.24 vs. GILD: 2.21 )
Ranked among companies with meaningful Dividend Yield only.
GILD' s Dividend Yield Range Over the Past 10 Years
Min: 0.36  Med: 1.44 Max: 2.29
Current: 2.21
0.36
2.29
Dividend Payout 0.16
GILD's Dividend Payout is ranked higher than
76% of the 121 Companies
in the Global Biotechnology industry.

( Industry Median: 0.32 vs. GILD: 0.16 )
Ranked among companies with meaningful Dividend Payout only.
GILD' s Dividend Payout Range Over the Past 10 Years
Min: 0.14  Med: 0.15 Max: 0.18
Current: 0.16
0.14
0.18
Forward Dividend Yield 2.31
GILD's Forward Dividend Yield is ranked higher than
72% of the 195 Companies
in the Global Biotechnology industry.

( Industry Median: 1.18 vs. GILD: 2.31 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 2.21
GILD's Yield on cost (5-Year) is ranked higher than
65% of the 257 Companies
in the Global Biotechnology industry.

( Industry Median: 1.56 vs. GILD: 2.21 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
GILD' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.36  Med: 1.42 Max: 2.29
Current: 2.21
0.36
2.29
3-Year Average Share Buyback Ratio 2.20
GILD's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 547 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. GILD: 2.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GILD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -16.3  Med: -1.1 Max: 6.1
Current: 2.2
-16.3
6.1

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 23.29
GILD's Price/Tangible Book is ranked lower than
91% of the 766 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. GILD: 23.29 )
Ranked among companies with meaningful Price/Tangible Book only.
GILD' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.33  Med: 10.37 Max: 214.73
Current: 23.29
2.33
214.73
Price/Projected FCF 0.80
GILD's Price/Projected FCF is ranked higher than
94% of the 161 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. GILD: 0.80 )
Ranked among companies with meaningful Price/Projected FCF only.
GILD' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.8  Med: 2.12 Max: 20.25
Current: 0.8
0.8
20.25
Price/Median PS Value 0.50
GILD's Price/Median PS Value is ranked higher than
83% of the 615 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. GILD: 0.50 )
Ranked among companies with meaningful Price/Median PS Value only.
GILD' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.5  Med: 1.48 Max: 5.5
Current: 0.5
0.5
5.5
Price/Peter Lynch Fair Value 0.28
GILD's Price/Peter Lynch Fair Value is ranked higher than
93% of the 57 Companies
in the Global Biotechnology industry.

( Industry Median: 1.57 vs. GILD: 0.28 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
GILD' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.28  Med: 0.94 Max: 9.13
Current: 0.28
0.28
9.13
Price/Graham Number 2.72
GILD's Price/Graham Number is ranked higher than
52% of the 176 Companies
in the Global Biotechnology industry.

( Industry Median: 2.73 vs. GILD: 2.72 )
Ranked among companies with meaningful Price/Graham Number only.
GILD' s Price/Graham Number Range Over the Past 10 Years
Min: 1.64  Med: 3.52 Max: 15.78
Current: 2.72
1.64
15.78
Earnings Yield (Greenblatt) (%) 17.00
GILD's Earnings Yield (Greenblatt) (%) is ranked higher than
96% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: -8.80 vs. GILD: 17.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GILD' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.5  Med: 7 Max: 17.5
Current: 17
0.5
17.5
Forward Rate of Return (Yacktman) (%) 65.09
GILD's Forward Rate of Return (Yacktman) (%) is ranked higher than
97% of the 117 Companies
in the Global Biotechnology industry.

( Industry Median: 14.98 vs. GILD: 65.09 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
GILD' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 0.7  Med: 5.9 Max: 65.5
Current: 65.09
0.7
65.5

More Statistics

Revenue (TTM) (Mil) $32,371
EPS (TTM) $ 11.35
Beta1.00
Short Percentage of Float1.19%
52-Week Range $76.67 - 111.11
Shares Outstanding (Mil)1,319.66

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 30,387 29,447 29,135 29,665
EPS ($) 11.84 11.69 12.26 11.75
EPS w/o NRI ($) 11.84 11.69 12.26 11.75
EPS Growth Rate
(3Y to 5Y Estimate)
-4.32%
Dividends Per Share ($) 1.84 1.91 1.88
» More Articles for GILD

Headlines

Articles On GuruFocus.com
Gilead Sciences: Cheap Growth or Value Trap? Sep 13 2016 
Zeke Ashton Invests in 10 New Holdings Sep 08 2016 
10 Low PE Stock Picks for the Enterprising Investor - September Sep 05 2016 
Gilead Was Smart to Let Medivation Slip Through its Fingers Aug 29 2016 
10 Undervalued Stocks for the Enterprising Investor Aug 26 2016 
Advanced Micro Devices and the Three Year Gamble Aug 22 2016 
10 Low PE Stock Picks for the Enterprising Investor - August Aug 21 2016 
5 Undervalued Stocks Near Lows for Enterprising Value Investors Aug 04 2016 
10 Most Undervalued Companies for the Enterprising Investor - July Jul 28 2016 
Gilead Sciences Is Still a Buy Jul 27 2016 

More From Other Websites
Cramer: Here Are the Reasons the Market Is Hated Sep 23 2016
Population Dynamics for Gilead’s HCV Products Sep 23 2016
Why Analysts Expect Gilead’s Revenue to Fall in 2016 and 2017 Sep 23 2016
Top 5 profitable Biotech stocks : September 23, 2016 Sep 23 2016
The Factors behind Gilead’s Discounted Valuation Sep 23 2016
Gilead (GILD) Stock Higher, Citigroup: Hepatitis C Drug Sales Improving Sep 23 2016
What Are Analysts’ Recommendations for Gilead Sciences? Sep 23 2016
Gilead Sciences: Are Hepatitis C Sales Getting Better? Sep 23 2016
Gilead Sciences Focuses on a Strong Inorganic Growth Strategy Sep 23 2016
Analyzing Gilead Sciences’ Stock Performance Sep 23 2016
Gilead Sciences: High Gross Margins despite Weak Sales Sep 23 2016
Why Is Gilead Sciences Trading at a Cheap Valuation? Sep 23 2016
Final Trade: GILD, TWTR & more Sep 22 2016
Gilead diving into M&A? Sep 22 2016
Gilead, Allergan Seen Trailing Intercept In Ongoing NASH Battle Sep 22 2016
Will Gilead Make a Good Fit for Allergan? (GILD) Sep 22 2016
Gilead Ends Bowel Disease Treatment Trials (GILD) Sep 22 2016
Gilead Sciences: Another Blow to R&D Strategy Sep 22 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)